In a report published Wednesday, MLV & Co. analyst Graig C. Suvannavejh reiterated a Buy rating on TG Therapeutics (NASDAQ: TGTX), and raised the price target from $10.00 to $16.00.
In the report, MLV & Co noted, “We now raise our PT on TGTX...
Vertex Pharmaceuticals (NASDAQ: VRTX) shares moved up 41.68% to $94.37. The volume of Vertex Pharmaceuticals shares traded was 2978% higher than normal. Vertex Pharma reported that its two phase 3 study of Lumacaftor in combination with ivacaftor...
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/TG+Therapeutics+%28TGTX%29+Enters+License+Agreement+for+IRAK4+with+Ligand+%28LGND%29%3B+Will+Get+Stock+%2B+Milestones/9607813.html for the full story.
TG Therapeutics, Inc.
(Nasdaq: TGTX), an innovative, clinical-stage biopharmaceutical company today
announced clinical results from its ongoing Phase I single agent study of
TG-1101 (ublituximab), the Company's novel glycoengineered...
The board of directors of Tredegar Corporation (NYSE:TG) declared a
quarterly dividend of nine cents ($0.09) per share on the company’s
common stock. The dividend is payable on July 1, 2014 to shareholders of
record at the...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.